Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

T. Mekhail · SciRah

Researcher profile · Semantic Scholar

T. Mekhail

Share profile

T. Mekhail — researcher profile on SciRah

h-index: 47
Works: 222
Citations: 19K

Most-cited papers

First-line crizotinib versus chemotherapy in ALK-positive lung cancer.
B. Solomon, T. Mok, Dong-Wan Kim, Yi-Long Wu +11 more
2014New England Journal of Medicine3,053 citations Open access
Semantic Scholar
Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer
S. Antonia, A. Villegas, D. Daniel, D. Vicente +26 more
2017New England Journal of Medicine2,703 citations Open access
Semantic Scholar
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
S. Antonia, A. Villegas, D. Daniel, D. Vicente +29 more
2018New England Journal of Medicine2,405 citations Open access
Semantic Scholar
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial.
H. West, M. McCleod, M. Hussein, A. Morabito +16 more
2019The Lancet Oncology1,417 citations
Semantic Scholar
Alectinib in Crizotinib-Refractory ALK-Rearranged Non-Small-Cell Lung Cancer: A Phase II Global Study.
S. Ou, J. Ahn, L. De Petris, R. Govindan +14 more
2016Journal of Clinical Oncology604 citations
Semantic Scholar
Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial.
A. Shaw, L. Gandhi, S. Gadgeel, Gregory Riely +15 more
2016The Lancet Oncology526 citations Open access
Semantic Scholar
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non-Small-Cell Lung Cancer.
B. Solomon, Dong-Wan Kim, Yi-Long Wu, K. Nakagawa +9 more
2018Journal of Clinical Oncology274 citations
Semantic Scholar
Intracranial Efficacy of Crizotinib Versus Chemotherapy in Patients With Advanced ALK-Positive Non-Small-Cell Lung Cancer: Results From PROFILE 1014.
B. Solomon, F. Cappuzzo, E. Felip, F. Blackhall +11 more
2016Journal of Clinical Oncology250 citations
Semantic Scholar
Treatment Outcomes and Safety of Mobocertinib in Platinum-Pretreated Patients With EGFR Exon 20 Insertion–Positive Metastatic Non–Small Cell Lung Cancer
Cai-Cun Zhou, S. Ramalingam, T. Kim, Sang-We Kim +14 more
2021JAMA Oncology224 citations Open access
Semantic Scholar
Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer
Peter J. Mazzone, Xiao-Feng Wang, Yao-Min Xu, T. Mekhail +5 more
2012Journal of Thoracic Oncology219 citations Open access
Semantic Scholar
Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial
Edward S. Kim, V. Velcheti, T. Mekhail, C. Yun +14 more
2022Nature Medicine167 citations Open access
Semantic Scholar
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non–Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations From a Phase 1/2 Trial
Gregory Riely, J. Neal, D. Camidge, A. Spira +18 more
2021Cancer Discovery167 citations Open access
Semantic Scholar
Programmed Death Ligand-1 (PD-L1) Expression in the Programmed Death Receptor-1 (PD-1)/PD-L1 Blockade: A Key Player Against Various Cancers.
Jian Guan, K. Lim, T. Mekhail, C. Chang
2017Archives of Pathology & Laboratory Medicine104 citations Open access
Semantic Scholar
First-line crizotinib versus pemetrexed–cisplatin or pemetrexed–carboplatin in patients (pts) with advanced ALK-positive non-squamous non-small cell lung cancer (NSCLC): results of a phase III study (PROFILE 1014)
T. Mok, Dong-Wan Kim, Yi-Long Wu, B. Solomon +8 more
2014103 citations
Semantic Scholar
Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib With Chemotherapy: Results From PROFILE 1014
B. Solomon, Dong-Wan Kim, Yi-Long Wu, K. Nakagawa +9 more
201883 citations
Semantic Scholar
Phase 2 prospective analysis of alectinib in ALK-positive, crizotinib-resistant non-small-cell lung cancer
A. Shaw, L. Gandhi, S. Gadgeel, Gregory Riely +15 more
2015The Lancet Oncology81 citations Open access
Semantic Scholar
IMpower130: Progression-free survival (PFS) and safety analysis from a randomised phase III study of carboplatin + nab-paclitaxel (CnP) with or without atezolizumab (atezo) as first-line (1L) therapy in advanced non-squamous NSCLC.
F. Cappuzzo, M. McCleod, M. Hussein, A. Morabito +16 more
2018Annals of Oncology66 citations Open access
Semantic Scholar
Safety and clinical activity results from a phase Ib study of alectinib plus atezolizumab in ALK+ advanced NSCLC (aNSCLC).
Dong-Wan Kim, S. Gadgeel, S. Gettinger, Gregory Riely +13 more
201855 citations
Semantic Scholar
Primary efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC).
E. Kim, V. Velcheti, T. Mekhail, T. Leal +13 more
2018Annals of Oncology53 citations Open access
Semantic Scholar
Final efficacy results from B-F1RST, a prospective phase II trial evaluating blood-based tumour mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC)
M. Socinski, V. Velcheti, T. Mekhail, Y. Chae +15 more
2019Annals of Oncology47 citations Open access
Semantic Scholar
Phase I/II study of bevacizumab with BKM120, an oral PI3K inhibitor, in patients with refractory solid tumors (phase I) and relapsed/refractory glioblastoma (phase II)
J. Hainsworth, K. Becker, T. Mekhail, S. Chowdhary +11 more
2019Journal of Neuro-Oncology45 citations
Semantic Scholar
A Randomized, Double-Blinded, Phase II Trial of Carboplatin and Pemetrexed with or without Apatorsen (OGX-427) in Patients with Previously Untreated Stage IV Non-Squamous-Non-Small-Cell Lung Cancer: The SPRUCE Trial.
D. Spigel, D. Shipley, D. Waterhouse, S. Jones +11 more
2019The Oncologist40 citations Open access
Semantic Scholar
Prospective clinical evaluation of blood-based tumor mutational burden (bTMB) as a predictive biomarker for atezolizumab (atezo) in 1L non-small cell lung cancer (NSCLC): Interim B-F1RST results.
V. Velcheti, Edward S. Kim, T. Mekhail, C. Dakhil +8 more
201840 citations
Semantic Scholar
Efficacy and Safety of Onartuzumab in Combination With First‐Line Bevacizumab‐ or Pemetrexed‐Based Chemotherapy Regimens in Advanced Non‐Squamous Non–Small‐Cell Lung Cancer
H. Wakelee, Z. Zvirbule, F. De Braud, Daniel C. Kingsley +12 more
2017Clinical Lung Cancer38 citations
Semantic Scholar
Phase II trial of Sorafenib in conjunction with chemotherapy and as maintenance therapy in extensive-stage small cell lung cancer
N. Sharma, N. Pennell, Myles S. Nickolich, B. Halmos +4 more
2014Investigational new drugs38 citations
Semantic Scholar
Efficacy and safety of the ALK inhibitor alectinib in ALK+ non-small-cell lung cancer (NSCLC) patients who have failed prior crizotinib: An open-label, single-arm, global phase 2 study (NP28673).
S. Ou, J. Ahn, L. De Petris, R. Govindan +14 more
201530 citations
Semantic Scholar
OA04.03 Mobocertinib in NSCLC With EGFR Exon 20 Insertions: Results From EXCLAIM and Pooled Platinum-Pretreated Patient Populations
C. Zhou, S. Ramalingam, B. Li, J. Fang +14 more
202129 citations Open access
Semantic Scholar
Metastatic Anaplastic Lymphoma Kinase-1 (ALK-1)-Rearranged Inflammatory Myofibroblastic Sarcoma to the Brain with Leptomeningeal Involvement: Favorable Response to Serial ALK Inhibitors: A Case Report
C. Yuan, M. J. Ma, John V. Parker, T. Mekhail
2017The American journal of case reports27 citations Open access
Semantic Scholar
Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors.
T. Mekhail, T. Rich, Lee S. Rosen, F. Chai +3 more
2016Journal of Clinical Oncology27 citations
Semantic Scholar
LBA50Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: Updated results from PROFILE 1014
T. Mok, D.-W. Kim, Y.-L. Wu, K. Nakagawa +8 more
201723 citations Open access
Semantic Scholar
Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
B. Halmos, N. Pennell, P. Fu, S. Saad +7 more
2015The Oncologist23 citations Open access
Semantic Scholar
Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.
S. Ramalingam, Cai-Cun Zhou, T. Kim, Sang-We Kim +13 more
202122 citations
Semantic Scholar
Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC
Dong-Wan Kim, S. Gadgeel, S. Gettinger, Gregory Riely +10 more
2022JTO Clinical and Research Reports20 citations Open access
Semantic Scholar
A phase II, open-label, multicenter study of the ALK inhibitor alectinib in an ALK+ non-small-cell lung cancer (NSCLC) U.S./Canadian population who had progressed on crizotinib (NP28761).
L. Gandhi, A. Shaw, S. Gadgeel, Gregory Riely +15 more
2015Journal of Clinical Oncology20 citations
Semantic Scholar
120O Pembrolizumab (Pembro) with or without lenvatinib (Lenva) in first-line metastatic NSCLC with PD-L1 TPS ≥1% (LEAP-007): A phase III, randomized, double-blind study
C.-H. J. Yang, A. Luft, E. de la Mora Jimenez, J. Lee +14 more
2021Annals of Oncology19 citations Open access
Semantic Scholar
Prognostic Value of KRAS Mutation Subtypes and PD-L1 Expression in Patients With Lung Adenocarcinoma.
Luwei Tao, Ruoyu Miao, T. Mekhail, Jingxin Sun +9 more
2020Clinical Lung Cancer17 citations
Semantic Scholar
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153
D. Waterhouse, L. Horn, C. Reynolds, D. Spigel +11 more
2018Cancer Chemotherapy and Pharmacology15 citations
Semantic Scholar
MA07.02 Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK-Positive Non-Small-Cell Lung Cancer
D. Camidge, S. Gadgeel, S. Ou, L. Gandhi +15 more
201715 citations Open access
Semantic Scholar
Mobocertinib (TAK-788) in EGFR Exon 20 Insertion+ Metastatic NSCLC: Patient-Reported Outcomes from EXCLAIM Extension Cohort
M. Garcia Campelo, Cai-Cun Zhou, S. Ramalingam, H. Lin +8 more
2021Journal of Clinical Medicine14 citations Open access
Semantic Scholar
1261MO Updated results from a phase I/II study of mobocertinib (TAK-788) in NSCLC with EGFR exon 20 insertions (exon20ins)
Gregory Riely, J. Neal, D. Camidge, A. Spira +16 more
202014 citations Open access
Semantic Scholar
A Single Center Retrospective Study of the Impact of COVID-19 Infection on Immune-related Adverse Events in Cancer Patients Receiving Immune Checkpoint Inhibitors
M. Guo, Jie-Ying Liu, Ruoyu Miao, Z. Ahmed +8 more
2022Journal of immunotherapy13 citations Open access
Semantic Scholar
3009 Activity of rociletinib in EGFR mutant NSCLC patients with a history of CNS involvement
A. Varga, D. Camidge, L. Sequist, H. Wakelee +12 more
201513 citations
Semantic Scholar
1225OOVERALL AND INTRACRANIAL (IC) EFFICACY RESULTS AND TIME TO SYMPTOM DETERIORATION IN PROFILE 1014: 1ST-LINE CRIZOTINIB VS PEMETREXED - PLATINUM CHEMOTHERAPY (PPC) IN PATIENTS (PTS) WITH ADVANCED ALK-POSITIVE NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC).
B. Solomon, E. Felip, F. Blackhall, Tony S. K. Mok +11 more
2014Annals of Oncology13 citations Open access
Semantic Scholar
Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol.
B. Levy, L. Paz-Ares, J. Bennouna, E. Felip +16 more
2019Clinical Lung Cancer11 citations Open access
Semantic Scholar
EGFR Genotyping of Matched Urine, Plasma, and Tumor Tissue in Patients With Non-Small-Cell Lung Cancer Treated With Rociletinib, an EGFR Tyrosine Kinase Inhibitor.
J. Goldman, C. Karlovich, L. Sequist, V. Meļņikova +23 more
2018JCO Precision Oncology11 citations
Semantic Scholar
988P Phase I/II study of mobocertinib in EGFR exon 20 insertion (ex20ins) + metastatic NSCLC (mNSCLC): Updated results from platinum-pretreated patients (PPP)
S. Ramalingam, C. Zhou, T. M. Kim, C.-H. J. Yang +11 more
2022Annals of Oncology10 citations Open access
Semantic Scholar
Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion–positive non–small cell lung cancer
Jie Yang, Cai-Cun Zhou, P. Jänne, S. Ramalingam +17 more
2022Expert Review of Anticancer Therapy9 citations Open access
Semantic Scholar
The prognostic value of KRAS mutation subtypes and PD-L1 expression in patients with lung adenocarcinoma.
Luwei Tao, Jingxin Sun, T. Mekhail, L. Meng +6 more
2019Journal of Clinical Oncology8 citations
Semantic Scholar
3101 Updated efficacy and safety results from a global phase 2, open-label, single-arm study (NP28673) of alectinib in crizotinib-refractory ALK+ non-small-cell lung cancer (NSCLC)
F. Barlesi, A. Dingemans, I. Ou, J. Ahn +16 more
20158 citations
Semantic Scholar
OA15.01 Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
A. Spira, S. Ramalingam, J. Neal, Z. Piotrowska +16 more
2021Journal of Thoracic Oncology7 citations Open access
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Gregory Riely×15
Invite
Gregory Riely — researcher profile on SciRah
M. Socinski×13
Invite
M. Socinski — researcher profile on SciRah
S. Gadgeel×12
Invite
S. Gadgeel — researcher profile on SciRah
Dong-Wan Kim×10
Invite
Dong-Wan Kim — researcher profile on SciRah

×10

Invite

E. Felip — researcher profile on SciRah

Invite

B. Solomon — researcher profile on SciRah

Invite

D. Camidge — researcher profile on SciRah

Invite

V. Bunn — researcher profile on SciRah

Invite

J. Paolini — researcher profile on SciRah

Invite

T. Usari — researcher profile on SciRah

Invite

H. West — researcher profile on SciRah

Invite

S. Ou — researcher profile on SciRah